Ginkgo Bioworks Announces Participation in Goldman Sachs 43rd Annual Global Healthcare Conference
Ginkgo Bioworks (NYSE: DNA) will participate in Goldman Sachs' 43rd Annual Global Healthcare Conference on June 15, 2022, at 10:40 a.m. PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) will participate in Goldman Sachs' 43rd Annual Global Healthcare Conference on June 15, 2022, at 10:40 a.m. PT. The company focuses on cell programming, providing a platform for biotechnology applications across various sectors including pharmaceuticals and agriculture. Ginkgo has also supported COVID-19 efforts such as pooled testing and vaccine optimization. Further details, including a webcast link, will be available on their investor relations website.
Positive
- Participation in a prominent healthcare conference may enhance visibility and investor interest.
- Ginkgo Bioworks is actively involved in COVID-19 response efforts, which can improve public perception and support.
Negative
- None.
Details
News Market Reaction – DNA
The recorded move for DNA in the trading session of this news was -15.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, June 10, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in Goldman Sachs' 43rd Annual Global Healthcare Conference, on June 15, 2022, at 10:40 a.m. PT.
Further details, a webcast link, and a replay of the presentation, if available, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit www.ginkgobioworks.com.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
MEDIA CONTACT:
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-goldman-sachs-43rd-annual-global-healthcare-conference-301566039.html
SOURCE Ginkgo Bioworks
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.